Pier Luigi Zinzani

University of Bologna, Italy

Born in Arenzano (GE) 9^th March, 1959
High School Qualification, in 1978
Graduated in Medicine and Surgery, with honours at the University of Bologna, in 1984
Obtained the Speciality in Hematology, with honours at the University of Bologna, in 1987.
Awarded a “Post-Doctoral Fellowship in Medical Oncology” released by the “Roger Williams Cancer Center” of Providence (USA) in 1989.
Chief of the clinical and translational program of the Lymphoma Unit at the Institute of Hematology and Medical Oncology “L. & A. Seràgnoli” from 1990.
Member of the Italian Society of Hematology from 1986
Member of the Italian Society of Experimental Hematology from 1987
Member of the American Society of Hematology from 1989
Member of the American Society of Clinical Oncology from 1989
Associated Professor at the Institute of Hematology and Medical Oncology “L. & A. Seràgnoli”, University of Bologna from November 2002.
Since 12 November 2018, Full Professor of Hematology at the University of Bologna.
Served as the principal investigator of more than 180 clinical trials (including phase 1 and 2 studies followed by expansion cohorts) in patients with Hodgkin, non-Hodgkin lymphoma, and chronic lymphocytic leukemia including national and international multicenter studies.
President of Italian Foundation on Lymphoma (FIL) from November 2013 to November 2015 and now he is a member of the Board of Directors.
Associate Editor of Annals of Oncology from January 2014 to December 2017 and he acts as a reviewer for journals such as Lancet Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Haematologica, Leukemia & Lymphoma, Leukemia, Clinical Lymphoma Myeloma.
He has presented his research at more than 450 national and international meetings.
He has authored over 580 peer-reviewed papers in journals such as New England Journal of Medicine, Blood, Journal of Clinical Oncology, Lancet Oncology, Annals of Oncology, Oncologist, Journal Hematology & Oncology, Haematologica.
His current research interest includes clinical trial methodology, prognostic factors in NHL, Hodgkin’s disease, chronic lymphocytic leukemia, new drugs development, and hairy cell leukemia.